CL2025001882A1 - Anticuerpos anti-pdl1/vegf y métodos de uso - Google Patents

Anticuerpos anti-pdl1/vegf y métodos de uso

Info

Publication number
CL2025001882A1
CL2025001882A1 CL2025001882A CL2025001882A CL2025001882A1 CL 2025001882 A1 CL2025001882 A1 CL 2025001882A1 CL 2025001882 A CL2025001882 A CL 2025001882A CL 2025001882 A CL2025001882 A CL 2025001882A CL 2025001882 A1 CL2025001882 A1 CL 2025001882A1
Authority
CL
Chile
Prior art keywords
antibody
methods
pdl1
vegf antibodies
binds
Prior art date
Application number
CL2025001882A
Other languages
English (en)
Inventor
Xue Jie
Xu Wenfeng
Jiang Wei-Dong
Lin Pei-Hua
Issafras Hassan
Chen Yu-Syaun
XIONG Shengen
Song Ge
Shan Yongqiang
Original Assignee
Shanghai Henlius Biotech Inc
Shanghai Henlius Biopharmaceutical Co Ltd
Shanghai Henlius Biologics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Henlius Biotech Inc, Shanghai Henlius Biopharmaceutical Co Ltd, Shanghai Henlius Biologics Co Ltd filed Critical Shanghai Henlius Biotech Inc
Publication of CL2025001882A1 publication Critical patent/CL2025001882A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente descripción se refiere a anticuerpos y derivados de anticuerpos que se unen a PDL1 y métodos de uso de los mismos. En ciertas modalidades, el anticuerpo o derivado de anticuerpo de la presente descripción comprende un anticuerpo de dominio único que se une a PDL1. En ciertas modalidades, el derivado de anticuerpo es un anticuerpo multiespecífico que se une a PDL1 y un antígeno adicional, p. ej., VEGF.
CL2025001882A 2022-12-29 2025-06-23 Anticuerpos anti-pdl1/vegf y métodos de uso CL2025001882A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2022143506 2022-12-29

Publications (1)

Publication Number Publication Date
CL2025001882A1 true CL2025001882A1 (es) 2025-11-07

Family

ID=91716470

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025001882A CL2025001882A1 (es) 2022-12-29 2025-06-23 Anticuerpos anti-pdl1/vegf y métodos de uso

Country Status (12)

Country Link
EP (1) EP4642813A2 (es)
JP (1) JP2026500781A (es)
KR (1) KR20250127163A (es)
CN (1) CN120569411A (es)
AU (1) AU2023417485A1 (es)
CL (1) CL2025001882A1 (es)
CO (1) CO2025010346A2 (es)
CR (1) CR20250254A (es)
IL (1) IL321672A (es)
MX (1) MX2025007599A (es)
PE (1) PE20252241A1 (es)
WO (1) WO2024140996A2 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108112254B (zh) * 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
US11407832B2 (en) * 2018-12-03 2022-08-09 Immuneonco Biopharmaceuticals (Shanghai) Inc. Recombinant protein targeting PD-L1 and VEGF
CN109942712B (zh) * 2019-04-01 2022-12-20 华博生物医药技术（上海）有限公司 抗pd-l1/vegf双功能抗体及其用途
CN114106190B (zh) * 2020-08-31 2025-04-08 普米斯生物技术(珠海)有限公司 一种抗vegf/pd-l1双特异性抗体及其用途
JP2024513205A (ja) * 2021-03-31 2024-03-22 ウーシー バイオロジクス アイルランド リミテッド 二重特異性抗ｐｄ－ｌ１／ｖｅｇｆ抗体およびその使用

Also Published As

Publication number Publication date
KR20250127163A (ko) 2025-08-26
CN120569411A (zh) 2025-08-29
EP4642813A2 (en) 2025-11-05
JP2026500781A (ja) 2026-01-08
PE20252241A1 (es) 2025-09-15
CR20250254A (es) 2026-01-12
WO2024140996A3 (en) 2024-08-08
MX2025007599A (es) 2025-09-02
IL321672A (en) 2025-08-01
CO2025010346A2 (es) 2025-10-20
AU2023417485A1 (en) 2025-06-26
WO2024140996A2 (en) 2024-07-04

Similar Documents

Publication Publication Date Title
MX2022011892A (es) Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del sindrome respiratorio agudo grave (sars-cov-2).
MX2023002374A (es) Anticuerpo biespecifico anti-calr-cd3 mutante escindido y composicion farmaceutica.
CL2018002490A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866)
MX375569B (es) Conjugados de pirrolobenzodiazepinas y anticuerpos
AR069797A1 (es) Anticuerpos especificos bivalentes
BR112018014760A2 (pt) anticorpos anti-ror1, anticorpos biespecíficos para ror1 x cd3 e métodos de uso dos mesmos
AR069775A1 (es) Anticuerpos bivalentes biespecificos
CR20160338A (es) Anticuerpos y métodos de uso
CO2023015593A2 (es) Terapias basadas en il2 y métodos de uso de las mismas
PE20241754A1 (es) Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
CO2022008314A2 (es) Anticuerpos anti–mertk y métodos de uso de los mismos
BR112018007842A2 (pt) imunoensaio para a detecção de cininogênio clivado de alto peso molecular, método, anticorpo isolado, kit para detectar um cininogênio de alto peso molecular clivado (hmwk)
AR119382A1 (es) Anticuerpos de pre-direccionamiento y métodos de uso
CL2023000595A1 (es) Anticuerpo que se une a vegf-a y ang2, y métodos de uso
CR20250226A (es) Anticuerpo anti-trem2 y usos del mismo
BR112022013403A2 (pt) Anticorpos anti-tigit, anticorpos multiespecíficos que compreendem os mesmos e métodos de uso dos mesmos
CO2025010346A2 (es) Anticuerpos anti-pdl1/vegf y métodos de uso.
MX2022001947A (es) Anticuerpos que se unen a las proteinas lrp5 y metodos de uso.
BR112022005666A2 (pt) Compostos engatadores de nk que se ligam a antígenos virais e métodos de uso
BR112021012022A2 (pt) Anticorpo que se liga ao vegf e à il-1beta e métodos de uso
CO2025010348A2 (es) Anticuerpos anti-pdl1 y métodos de uso
BR112023021557A2 (pt) Anticorpos anti-gpc3 e métodos de uso
MX2021001604A (es) Tratamiento del cáncer con un anticuerpo.
MX2025013360A (es) Conjugado de anticuerpo anti-pdl1-farmaco y uso
CO2026003714A2 (es) Anticuerpo que se une a c3bbb